GlassScriptPhysician profile
Michael T Farrell
NPI 1922095421
$12,678.06
in general payments reported to CMS, 2019-2025
45 companies · $3,168 in 2025
The $3,168 reported for 2025 was more than what 87% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
See the full distribution for Gastroenterology (Internal Medicine)
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,301 · 2020: $466 · 2021: $1,442 · 2022: $1,781 · 2023: $1,954 · 2024: $2,566 · 2025: $3,168.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $6,691 · Travel and Lodging: $888 · Education: $109.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $6,690.83 |
| Travel and Lodging | $888.00 |
| Education | $109.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $5,101.22 | 2019-2025 | |
| Janssen Biotech, INC. | $1,302.08 | 2019-2025 | Tremfya, Stelara |
| Takeda Pharmaceuticals U.S.A., INC. | $911.42 | 2019-2025 | Entyvio |
| Abbott Laboratories | $888.00 | 2025 | Proclaim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $726.87 | 2019-2025 | Xifaxan, Trulance, Relistor |
| Genzyme Corporation | $396.08 | 2022-2025 | |
| Phathom Pharmaceuticals, INC. | $301.52 | 2024 | Voquezna |
| Pfizer INC. | $234.93 | 2019-2025 | |
| Celgene Corporation | $227.15 | 2021-2023 | Zeposia |
| Lilly USA, LLC | $202.83 | 2025 | Omvoh |
| Qol Medical, LLC | $184.21 | 2019-2024 | Sucraid, Sucraid |
| Gilead Sciences, INC. | $171.02 | 2019-2024 | |
| Allergan, INC. | $150.23 | 2019-2020 | |
| Intra-Sana Laboratories | $141.26 | 2022 | |
| Ardelyx, INC. | $134.46 | 2022-2025 | Ibsrela |
Show all 45 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $121.96 | 2025 | Wegovy |
| Olympus America INC. | $116.51 | 2023 | Single Use Electrosurgical Knife Kd-655 |
| Ironwood Pharmaceuticals, INC | $109.29 | 2021-2023 | Linzess |
| Aimmune Therapeutics, INC. | $101.91 | 2024-2025 | Vowst, Zenpep |
| Intercept Pharmaceuticals, INC. | $92.23 | 2020-2025 | Ocaliva |
| Janssen Scientific Affairs, LLC | $91.07 | 2021 | |
| Ferring Pharmaceuticals INC. | $82.59 | 2019-2023 | Rebyota |
| Amgen INC. | $81.21 | 2023 | Avsola, Amjevita |
| Merck Sharp & Dohme LLC | $66.96 | 2021-2024 | Dificid, Keytruda |
| Celltrion USA INC. | $63.78 | 2024 | Zymfentra |
| Shire North American Group INC | $57.87 | 2019 | |
| Nestle Healthcare Nutrition INC. | $52.47 | 2023 | |
| Madrigal Pharmaceuticals | $51.68 | 2025 | Rezdiffra |
| Daiichi Sankyo INC. | $51.43 | 2024-2025 | Injectafer |
| Alexion Pharmaceuticals, INC. | $48.74 | 2022 | |
| Ipsen Biopharmaceuticals, INC | $46.48 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $45.55 | 2022-2023 | Dupixent |
| Organon LLC | $45.15 | 2021-2023 | Hadlima |
| Vivus LLC | $31.64 | 2025 | Qsymia, Pancreaze |
| Braintree Laboratories, INC. | $31.39 | 2022-2023 | Suflave |
| Alnylam Pharmaceuticals INC. | $29.80 | 2021 | |
| Covidien LP | $29.22 | 2019 | |
| Sandoz INC. | $27.24 | 2025 | Hyrimoz |
| Biocon Biologics INC | $21.74 | 2025 | Hulio |
| Mylan Institutional INC. | $21.43 | 2023 | Hulio |
| Cumberland Pharmaceuticals, INC. | $19.64 | 2024 | Sancuso |
| Apollo Endosurgery US INC | $17.57 | 2023 | Overstitch Endoscopic Suturing System |
| Ambu INC. | $16.60 | 2021 | |
| Redhill Biopharma INC. | $16.44 | 2020 | |
| Alfasigma USA, INC. | $15.19 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Farrell listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.